Innovative drug candidate for intractable brain disorders, entering clinical trials

Strategic commercialization support including brand building and expert consulting for companies with unique value


2024 support for preliminary technology evaluation for designated “Strong SMEs”

Support for FDA IND approval for CV-02

Pipeline of clinical-stage drug candidates for intractable brain diseases

First-class selective DDR1 inhibitor (Discoidin Domain Receptor 1) for treatment of KRAS G12X mutation-positive cancer and rare diseases

To develop next-generation GPCR platforms for discovering novel therapies for intractable pruritus based on the modulation of non-histaminergic itch signaling.

Expansion of application for intractable cardiovascular diseases through CV-01, the world’s first Keap1 pathway-targeting non-clinical candidate

Non-clinical and clinical strategy development and customized consulting support reflecting unmet medical needs

Completion of non-clinical trials and IND approval for an Alzheimer’s disease therapeutic candidate based on glial cell modulation

Completion of non-clinical trials and IND approval for a third-generation multiple sclerosis therapeutic candidate based on biased signaling modulation that overcomes cardiac side effect limitations

Expansion of indications for the inflammatory disease therapeutic clinical candidate (CV-01)

GMP production of drug substance (DS) for CV-01 to support IND and clinical development


Evaluating the efficacy of a best-in-class candidate for intractable inflammatory bowel disease

Preparation of non-clinical reference standards for the development of innovative new drugs based on small molecule compounds.

Development of small molecule therapeutics targeting transcription factors for intractable brain diseases